Eric,
I see your concern(s) in a different light that indicates nothing has happened to the relationship other than the fact that reporting amortization of prepaid royalties ended last quarter. If anything happened that was a material event,I believe the company would be required to file an 8-K. They would probably also put out a press release, as they always seem to do, when there is news, or both. From what I can read-there is plenty of proof that the MCT- XenoTech relationship is not "in jeopardy"; all anyone needs to do is look at the events section on MultiCell's web site or on XenoTech's web site to see that the 2 companies have plans to work closely together this summer:
XenoTech Drug Metabolism Symposium
June 6-7, 2005
Kansas City, MO
Register for Symposium
DDI-2005
June 15-17, 2005
Xenotech will exhibit and Pfizer presents Fa2N-4 at DDI-2005
at the Bell Harbor Conference Center, Seattle, WA, USA
isciencex.com
Regarding your opinion of: "Around 30 Large Pharmas were said to be in 90 day evaluations with the cells at last years shareholder meeting (almost 1 full year ago), and there is only 1 paying customer"
Whatever number of pharmaceutical companies are evaluating MCT's immortalized hepatocytes, obviously, there are at least that many paying customers. Pharmaceutical companies do not usually evaluate cell lines for free, in my opinion. They buy them! Also we all know (who have read the filings) that 2 of the top pharmas in the world, Pfizer and a major Japanese company, have paid well, IMHO for the privilege of using the cells. Also, don't forget what was published last May:" The XenoTech and Roche* results are very significant. Not only have these laboratories confirmed that MCT cell lines are a reliable tool to study induction of key drug metabolizing proteins, but more importantly, taken together these findings indicate that our immortalized hepatocytes can be employed to study the complex metabolism of new drug candidates and identify potential drug-drug interactions. We anticipate that the greatest impact of MCT technology will be to red-flag those new drug candidates that may have undesirable side effects much earlier in the overall drug discovery process, thus providing significant savings to the pharmaceutical industry."
*Hoffman-LaRoche
Are you currently a shareholder? Have you sold any at this point? It is tough to tell by the messages your are posting! As I communicated in my message to Lexi, I have not sold even one share and don't intend to with the potential I believe this stock currently has; and in more than a couple of different areas within the biotech industry...
Regards,
Shawn
PS: Again, even though I do not like to see a reverse split being announced, I am pleased to see that the accountants removed the going concern verbiage from the MUCL Report! |
